DRNA Dicerna Pharmaceuticals Inc

Price (delayed)

$36.18

Market cap

$2.78B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.6

Enterprise value

$2.67B

Highlights
Dicerna Pharmaceuticals's revenue has increased by 8% from the previous quarter
Dicerna Pharmaceuticals's gross profit has increased by 8% from the previous quarter
The quick ratio has grown by 10% YoY but it has contracted by 7% from the previous quarter
The company's EPS rose by 5% YoY but it fell by 5% QoQ
Dicerna Pharmaceuticals's debt has surged by 118% YoY
DRNA's equity is down by 29% YoY and by 8% QoQ

Key stats

What are the main financial stats of DRNA
Market
Shares outstanding
76.9M
Market cap
$2.78B
Enterprise value
$2.67B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
21.84
Price to sales (P/S)
15.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.04
Earnings
Revenue
$177.88M
EBIT
-$120.19M
EBITDA
-$116.84M
Free cash flow
-$186.42M
Per share
EPS
-$1.6
Free cash flow per share
-$2.44
Book value per share
$1.66
Revenue per share
$2.33
TBVPS
$8.96
Balance sheet
Total assets
$683.41M
Total liabilities
$557.01M
Debt
$51.64M
Equity
$126.4M
Working capital
$412.35M
Liquidity
Debt to equity
0.41
Current ratio
3.26
Quick ratio
3.16
Net debt/EBITDA
0.92
Margins
EBITDA margin
-65.7%
Gross margin
100%
Net margin
-67.6%
Operating margin
-65.9%
Efficiency
Return on assets
-17.1%
Return on equity
-82.9%
Return on invested capital
-34.2%
Return on capital employed
-24%
Return on sales
-67.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DRNA stock price

How has the Dicerna Pharmaceuticals stock price performed over time
Intraday
1.12%
1 week
-3.16%
1 month
32%
1 year
47.31%
YTD
64.23%
QTD
41.49%

Financial performance

How have Dicerna Pharmaceuticals's revenue and profit performed over time
Revenue
$177.88M
Gross profit
$177.88M
Operating income
-$117.15M
Net income
-$120.22M
Gross margin
100%
Net margin
-67.6%
DRNA's operating margin has soared by 71% YoY and by 4.4% from the previous quarter
Dicerna Pharmaceuticals's net margin has surged by 68% YoY
Dicerna Pharmaceuticals's revenue has increased by 8% from the previous quarter
Dicerna Pharmaceuticals's gross profit has increased by 8% from the previous quarter

Growth

What is Dicerna Pharmaceuticals's growth rate over time

Valuation

What is Dicerna Pharmaceuticals stock price valuation
P/E
N/A
P/B
21.84
P/S
15.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.04
The company's EPS rose by 5% YoY but it fell by 5% QoQ
The price to book (P/B) is 84% more than the last 4 quarters average of 11.9
DRNA's equity is down by 29% YoY and by 8% QoQ
The stock's price to sales (P/S) is 19% more than its last 4 quarters average of 13.0
Dicerna Pharmaceuticals's revenue has increased by 8% from the previous quarter

Efficiency

How efficient is Dicerna Pharmaceuticals business performance
The company's return on sales has surged by 68% YoY
The company's return on invested capital rose by 36% YoY
The return on assets rose by 24% year-on-year but it has declined by 10% since the previous quarter
Dicerna Pharmaceuticals's return on equity has decreased by 16% QoQ and by 11% YoY

Dividends

What is DRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DRNA.

Financial health

How did Dicerna Pharmaceuticals financials performed over time
The total assets is 23% greater than the total liabilities
The total assets has declined by 12% year-on-year and by 3.5% since the previous quarter
DRNA's current ratio is up by 12% YoY but it is down by 6% QoQ
Dicerna Pharmaceuticals's debt is 59% lower than its equity
Dicerna Pharmaceuticals's debt has surged by 118% YoY
DRNA's equity is down by 29% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.